Republic of MoldovaTuberculosis profile
Population  2014 4.1 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.32 (0.3–0.34) 7.8 (7.4–8.3)
Mortality (HIV+TB only) 0.11 (0.089–0.14) 2.7 (2.2–3.3)
Prevalence  (includes HIV+TB) 9.3 (4.9–15) 229 (120–372)
Incidence  (includes HIV+TB) 6.2 (5.5–7) 153 (135–172)
Incidence (HIV+TB only) 0.5 (0.43–0.58) 12 (11–14)
         
Case detection, all forms (%) 65 (58–74)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 24 (21–26) 62 (59–65)
MDR-TB cases among notified pulmonary
TB cases
690 (630–760) 830 (790–870)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 1 774   477
Pulmonary, clinically diagnosed 1 157   276
Extrapulmonary 343   31
       
Total new and relapse 4 058    
Previously treated, excluding relapses 578    
Total cases notified 4 636    
Among 4 058 new and relapse cases:
114 (3%) cases aged under 15 years; male:female ratio: 2.5
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 1 764 (99%) 831 (61%) 2 595
Laboratory-confirmed RR-/MDR-TB cases     925
Patients started on MDR-TB treatment ***     930
TB/HIV 2014 Number (%)
TB patients with known HIV status 4 426 (95)
HIV-positive TB patients 338 (8)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 140 (41)
HIV-positive people screened for TB 4 025  
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (80) 3 889
Previously treated cases, excluding relapse, registered in 2013 (39) 357
HIV-positive TB cases, all types, registered in 2013 (52) 247
RR-/MDR-TB cases started on second-line treatment in 2012 (59) 856
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 1.4
Culture (per 5 million population) 4.9
Drug susceptibility testing (per 5 million population) 4.9
Sites performing Xpert MTB/RIF 28
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 17
% Funded domestically 59%
% Funded internationally 41%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-06-25 Data: www.who.int/tb/data